Macquarie Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-70,000
| Closed | -$1.69M | – | 1757 |
|
|
2023
Q1 | $1.69M | Hold |
70,000
| – | – | ﹤0.01% | 1212 |
|
|
2022
Q4 | $740K | Hold |
70,000
| – | – | ﹤0.01% | 1466 |
|
|
2022
Q3 | $315K | Hold |
70,000
| – | – | ﹤0.01% | 1576 |
|
|
2022
Q2 | $280K | Hold |
70,000
| – | – | ﹤0.01% | 1661 |
|
|
2022
Q1 | $512 | Hold |
70,000
| – | – | ﹤0.01% | 1646 |
|
|
2021
Q4 | $393K | Hold |
70,000
| – | – | ﹤0.01% | 1675 |
|
|
2021
Q3 | $448K | Hold |
70,000
| – | – | ﹤0.01% | 1692 |
|
|
2021
Q2 | $590K | Hold |
70,000
| – | – | ﹤0.01% | 1674 |
|
|
2021
Q1 | $735K | Hold |
70,000
| – | – | ﹤0.01% | 1464 |
|
|
2020
Q4 | $1.19M | Hold |
70,000
| – | – | ﹤0.01% | 1267 |
|
|
2020
Q3 | $898K | Hold |
70,000
| – | – | ﹤0.01% | 1259 |
|
|
2020
Q2 | $988K | Sell |
70,000
-6,725
| -9% | -$84.9K | ﹤0.01% | 1209 |
|
|
2020
Q1 | $706K | Buy |
76,725
+6,725
| +10% | +$86.7K | ﹤0.01% | 1184 |
|
|
2019
Q4 | $1.04M | Hold |
70,000
| – | – | ﹤0.01% | 1230 |
|
|
2019
Q3 | $478K | Hold |
70,000
| – | – | ﹤0.01% | 1379 |
|
|
2019
Q2 | $847K | Buy |
+70,000
| New | +$381K | ﹤0.01% | 1256 |
|
Other funds holding PRVB
Macquarie Group's PRVB Position: Q2 2023 in Review
Macquarie Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 70,000 shares — an estimated $1.69M sold.
Macquarie Group first reported a position in PRVB in Q2 2019 and held it in 16 quarters. The position peaked at $1.69M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Macquarie Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Macquarie Group sold 70,000 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.69M.
- Macquarie Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Macquarie Group's Provention Bio, Inc. Common Stock position peaked at $1.69M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Macquarie Group's 13F filing for Q2 2023, filed 14 Aug 2023.